started · updated
AI accelerates drug discovery and cancer care with 200+ drugs in clinical trials
Artificial intelligence is rapidly transforming the landscape of oncology and drug discovery. As of early 2026, over 200 AI-original drugs are in various stages of clinical development globally. A notable milestone includes Insilico Medicine's rentosertib, which became the first drug discovered entirely via AI to enter Phase III clinical trials in July 2026.
In clinical applications, AI is enhancing early cancer detection and trial efficiency. The MASAI trial in Sweden demonstrated that AI-assisted mammography can achieve higher detection rates than traditional methods without increasing false positives. Additionally, the NIH's TrialGPT has shown the ability to reduce clinical trial screening times by 42.6%.
Despite these advancements, industry experts warn that high-quality data scarcity remains a critical bottleneck. While AI models are becoming more accessible through open-source weights, the true competitive advantage is shifting toward data ecosystems, specifically the ability to create feedback loops between digital models and physical laboratory experiments. Forums in Shanghai and Mountain View have highlighted that the future of precision health depends on integrating AI with multi-omics and genomics while maintaining human expertise to validate complex biological results.
Entities
Amgen · Bay Area Taiwanese Biotech Association · Insilico Medicine · National Institutes of Health · Shanghai · Shanghai Institute for AI for Science · Tencent
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] The global AI drug discovery sector has accumulated approximately $60 billion in investment since 2019. unwire.hk
- [○ 1 SOURCE] The 2026 US-Taiwan Bioscience Forum in Mountain View focused on cross-disciplinary innovation for precision health using AI. www.epochtimes.com
- [○ 1 SOURCE] The MASAI trial in Sweden involving over 105,000 women demonstrated that AI-assisted mammography detection rates are higher than traditional double-reading by radiologists without increasing false-pos technews.tw
- [○ 1 SOURCE] As of early 2026, more than 200 AI-original drugs are in clinical development stages globally. unwire.hk
- [○ 1 SOURCE] The 2026 Disease Prevention and Results Transformation Conference in Shanghai focused on AI-empowered drug R&D and clinical applications. www.eeo.com.cn
- [○ 1 SOURCE] Experts noted that the lack of high-quality data remains a significant bottleneck for AI-driven biopharmaceutical development. unwire.hk
- [○ 1 SOURCE] The NIH-developed TrialGPT can reduce clinical trial screening time by 42.6% in tests. technews.tw
- [○ 1 SOURCE] Insilico Medicine's rentosertib is the first drug discovered entirely through AI to enter Phase III clinical trials, starting in July 2026. unwire.hk